Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

August 31, 2006

Conditions
EsophagitisPneumonitisNon-Small Cell Lung Carcinoma
Interventions
DRUG

Amifostine

Trial Locations (24)

10003

Beth Israel Hospital, New York

11040

Long Island Jewish Medical Center, New Hyde Park

14623

Upstate NY Cancer R&E Foundation, Rochester

18337

Cancer Center of Upper Delaware Valley, Milford

19401

Montgomery Cancer Center, Norristown

20817

Center for Cancer & Blood Disorders, Bethesda

21061

Chesapeake Oncology-Hematology Associates, Glen Burnie

21229

St. Agnes Health Care, Baltimore

24541

The Center for Radiation Oncology, Danville

28401

New Hanover Radiation, Wilmington

29406

Charleston Cancer Center, Charleston

32174

Ormand Memorial Cancer Center, Ormand Beach

33613

University Community Hospital-Center for Cancer Care, Tampa

34239

Sarasota Memorial Hospital, Sarasota

34452

Florida Wellcare Alliance, Inverness

34652

Florida Community Cancer Center, New Port Richey

65807

St. John's Medical Research, Springfield

90048

Cedars Sanai, Los Angeles

95816

Radiation Oncology Center, Sacramento

98055

Valley Medical Center, Renton

98201

Providence Everett Medical Center, Everett

06790

The Center for Cancer Care, Torrington

40536-0293

University of Kentucky, Lexington

08103

Cooper University Hospital, Camden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00081315 - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter